NU6027 is primarily used in cancer research due to its ability to inhibit cyclin-dependent kinases (CDKs), especially CDK2. This inhibition disrupts the cell cycle in tumor cells, preventing uncontrolled proliferation. It has shown potential in enhancing the effectiveness of DNA-damaging agents like chemotherapy and radiation by impairing DNA repair mechanisms in cancer cells. Because of this, NU6027 is often studied in combination therapies to increase tumor sensitivity while reducing the required doses of more toxic treatments. Its role as a research tool helps in understanding cell cycle regulation and developing targeted anticancer drugs.